The low immune activity along with activation of genes that are associated with HCC development in low-ARID1A subtype indicate that ARID1A may have tumor suppressive activity and suggests the possibility of ARID1A as a prognostic biomarker in HCC patients. This evidence concerns the gene ARID1A and hepatocellular carcinoma.